Rick Klausner
North America, California, United States
Description
Rick Klausner is a Chief Executive Officer at Lyell Immunopharma.
Investor Profile
Rick Klausner has backed more than 4 startups, with 0 new investments in the last 12 months alone. The firm has led 3 rounds, about 75% of its total and boasts 0 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series B, Convertible Note rounds (top funding stages).
- Majority of deals are located in United Kingdom, United States, The Netherlands.
- Strong thematic focus on Biotechnology, Health Care, Commercial.
Stage Focus
- Series A (50%)
- Series B (25%)
- Convertible Note (25%)
Country Focus
- United Kingdom (25%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- United States (25%)
- The Netherlands (25%)
- Israel (25%)
Industry Focus
- Biotechnology
- Health Care
- Commercial
- Genetics
- Life Science
- Therapeutics
- Food And Beverage
- Food Processing
- Innovation Management
- Apps
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'/%3e%3cuse xlink:href='%23a' transform='rotate(144 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(216 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(288 450 300)'/%3e%3c/svg%3e)
